Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMV8MKP)

Drug Name
A-315456 Drug Info
Synonyms
CHEMBL362863; N-[3-(cyclohexylidene(1H-imidazol-4-ylmethyl)phenyl]ethanesulfonamide; NCGC00015076-01; AC1O7FZN; Lopac-A-6351; Lopac0_000059; MLS002153477; CTK8F7477; HMS3370M22; HMS3260K19; HMS2235H14; ZINC9229227; Tox21_500059; BDBM50160163; LP00059; CCG-204154; NCGC00093573-02; NCGC00015076-03; NCGC00093573-01; NCGC00015076-02; NCGC00260744-01; NCGC00015076-04; SMR001230830; EU-0100059; A-315456, > A 6351; SR-01000076218; SR-01000076218-1
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
6603710
TTD Drug ID
DMV8MKP

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Adrenergic receptor alpha-1A (ADRA1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SILODOSIN DMJSBT6 Benign prostatic hyperplasia GA90 Approved [1]
NAFTOPIDIL DMQ8R4E Hypertension BA00-BA04 Approved [1]
Tamsulosin DM5QF9V Benign prostatic hyperplasia GA90 Approved [2]
Xatral DMLHOA0 Benign prostatic hyperplasia GA90 Approved [3]
Dutasteride + tamsulosin DM6P8HU Benign prostatic hyperplasia GA90 Phase 3 [4]
Besipirdine DMLVNTA Cognitive impairment 6D71 Phase 3 [5]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [6]
PMID30124346-Compound-LDT8 DM5MUNG Benign prostatic hyperplasia GA90 Patented [7]
PMID30124346-Compound-LDT66 DMJMTNL Benign prostatic hyperplasia GA90 Patented [7]
TIOSPIRONE DME5QDP N. A. N. A. Discontinued in Phase 3 [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor alpha-1A (ADRA1A) TTNGILX ADA1A_HUMAN Inhibitor [1]

References

1 Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 Pharma & Vaccines. Product Development Pipeline. April 29 2009.
4 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
5 Alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther. 1997 Apr;281(1):337-46.
6 A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
7 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
8 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.